// App-Quantinova.ai

: Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial

Researchers

Presenter

  • D K McGuire

Principal Investigators

  • B Zinman

  • S E Inzucchi

  • S D Anker

  • C Wanner

  • S Kaspers

  • J T George

  • U Elsasser

  • H J Woerle

  • S S Lund

Medical Centers

  • University of Texas Southwestern Medical School, Dallas, United States of America

  • Lunenfeld-Tanenbaum Research Institute of Sinai Health System, University of Toronto, Toronto, Ontario, Canada

  • Section of Endocrinology, Yale University School of Medicine, New Haven, United States of America

  • Division of Cardiology and Metabolism, Charité - Universitätsmedizin Berlin, Berlin, Germany

  • Würzburg University Clinic, Würzburg, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

Locations

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • The Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved